Prevalence of resistance to three fluoroquinolones: Assessment of levofloxacin disk test error rates and surrogate predictors of levofloxacin susceptibility

Antimicrobial Agents and Chemotherapy

Volumn 40, Issue 7, 1996, Pages 1633-1639

  Fuchs, Peter C ^a   Barry, Arthur L ^a   Brown, Steven D ^a   Allen, S ^b   Bauman, M ^c   Bruckner, D ^d   Hindler, J ^d   Doern, O ^e   Ferraro, M J ^f   Hardy, D ^g   Jenkins, S ^h   McLaughlin, J ⁱ   Murray, P ^j   Sewell, D ^k  

^a CLINICAL MICROBIOLOGY INSTITUTE   (United States)

^b INDIANA UNIVERSITY MEDICAL CENTER   (United States)

^c PROVIDENCE ST VINCENT MEDICAL CENTER   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

^f MASSACHUSETTS GENERAL HOSPITAL   (United States)

^g STRONG MEMORIAL HOSPITAL   (United States)

^h UNIVERSITY OF FLORIDA HEALTH JACKSONVILLE   (United States)

ⁱ UNIVERSITY OF NEW MEXICO HOSPITAL   (United States)

^j BARNES JEWISH HOSPITAL   (United States)

^k PORTLAND VA MEDICAL CENTER   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

CIPROFLOXACIN; LEVOFLOXACIN; OFLOXACIN; QUINOLINE DERIVED ANTIINFECTIVE AGENT;

ANTIBIOTIC RESISTANCE; ARTICLE; BACTERIUM ISOLATION; CLINICAL TRIAL; DIAGNOSTIC ACCURACY; DIAGNOSTIC ERROR; HUMAN; HUMAN CELL; MINIMUM INHIBITORY CONCENTRATION; MULTICENTER STUDY; PREVALENCE; PRIORITY JOURNAL; PSEUDOMONAS AERUGINOSA; QUALITY CONTROL; SPECIES DIFFERENCE; UNITED STATES;

EID: 8944231642     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/aac.40.7.1633     Document Type: Article

References (29)

1. Bale, M. J., K. N. Jones, M. E. Erwin, and the Quality Control Study Group. 1994. Minimum inhibitory concentration quality-control guidelines for biapenem, DU-6859a, FK-037, levofloxacin, grepafloxacin, and ceftizoxime when using various National Committee for Clinical Laboratory Standards test methods. Diagn. Microbiol. Infect. Dis. 19:65-68.
2. Barry, A., P. Fuchs, F. Tenover, S. Allen, D. Hardy, J. Jorgensen, J. McLaughlin, and L. Reller. 1994. Interpretive criteria and quality control for antimicrobial susceptibility tests of levofloxacin. Eur. J. Clin. Microbiol. Infect. Dis. 13:822-826.
3. Cherubin, C. E., R. H. K. Eng, S. M. Smith, and E. N. Tan. 1992. A comparison of antimicrobial activity of ofloxacin, L-ofloxacin, and other oral agents for respiratory pathogens. Diagn. Microbiol. Infect. Dis. 15:141-144.
4. Cormican, M. G., and R. N. Jones. 1995. Susceptibility to levofloxacin predicted from in vitro susceptibility testing results obtained with ciprofloxacin and with ofloxacin. J. Clin. Microbiol. 33:215-216.
5. Daum, T. E., D. R. Schaberg, M. S. Terpenning, W. S. Sottile, and C. A. Kauffman. 1980. Increasing resistance of Staphylococcus aureus to ciprofloxacin. Antimicrob. Agents Chemother. 34:1862-1863.
6. Dholakia, N., K. V. Rolston, D. H. Ho, B. LeBlanc, and G. P. Bodey. 1994. Susceptibilities of bacterial isolates from patients with cancer to levofloxacin and other quinolones. Antimicrob. Agents Chemother. 38:848-852.
7. Foleno, B., and K. P. Fu. 1992. In vitro activity of L-ofloxacin against norfloxacin-resistant coagulase-negative staphylococci. Diagn. Microbiol. Infect. Dis. 15:557-559.
8. Foleno, B. D., S. C. Lafredo, and K. P. Fu. 1983. In vitro activity of levofloxacin, ofloxacin and other quinolones against coagulase-negative staphylococci. Microbiology 39:120-123.
9. Fu, K. P., S. C. Lafredo, K. B. Foleno, D. M. Isaacson, J. F. Barrett, A. J. Tobia, and M. E. Rosenthale. 1992. In vitro and in vivo antibacterial activities of levofloxacin (l-ofloxacin), an optically active ofloxacin. Antimicrob. Agents Chemother. 36:860-866.
10. Fuchs, P. C., R. N. Jones, A. L. Barry, T. L. Gavan, and The Collaborative Antimicrobial Susceptibility Test Group. 1989. Ofloxacin susceptibility testing quality control parameters for microdilution and disk diffusion, and confirmation of disk diffusion interpretive criteria. J. Clin. Microbiol. 27:49-52.
11. Fujimoto, T., and S. Mitsuhashi. 1990. In vitro antibacterial activity of DR-3355, S-(-)-isomer of ofloxacin. Chemotherapy 36:268-276.
12. Goudwin, S. D., H. A. Gallis, A. T. Chow, F. A. Wong, S. C. Flor, and J. A. Bartlett. 1994. Pharmacokinetics and safely of levofloxacin in patients with human immunodeficiency virus infection. Antimicrob. Agents Chemother. 38:799-804.
13. Hayakawa, I., S. Atarash, K. S. Yokohama, M. Imamura, K. Sakano, and M. Furukawa. 1986. Synthesis and antibacterial activities of optically active ofloxacin. Antimicrob. Agents Chemother. 29:163-164.
14. Houston, A. K., and R. N. Jones. 1994. Postantibiotic effect of DU-6859a and levofloxacin as compared with ofloxacin. Diagn. Microbiol. Infect. Dis. 18: 57-59.
15. Imamura, M., S. Shibamura, I. Hayakawa, and Y. Osada. 1987. Inhibition of DNA gyrase by optically active ofloxacin. Antimicrob. Agents Chemother. 31:325-327.
16. Kiesel, N., K. H. Geweniger, P. Koletzki, D. Isert, M. Limbert, A. Markus, G. Riess, H. Schramm, and P. Iyer. 1995. Chemotherapeutic activity of levofloxacin (HR 355, DR-3355) against systemic and localized infections in laboratory animals. J. Antimicrob. Chemother. 35:805-819.
17. Metzler, C. M., and R. M. DeHaan. 1974. Susceptibility of anaerobic bacteria: statistical and clinical criteria. J. Infect. Dis. 130:588-596.
18. Morissey, I., and J. T. Smith. 1994. Activity of 4-quinolones against Pseudomonas aeruginosa. Arzneim-Forsch./Drug Res. 44:1157-1161.
19. Nakashima, M., T. Uematsu, M. Kanamaru, O. Okazaki, and H. Hakususi. 1992. Phase I study of levofloxacin (S)-(-)-ofloxacin. Jpn. J. Clin. Pharmacol. Ther. 23:515-520.
20. National Committee for Clinical Laboratory Standards. 1993. Performance standards for antimicrobial disk susceptibility tests. Approved standard M2-A5. National Committee for Clinical Laboratory Standards, Villanova, Pa.
21. National Committee for Clinical Laboratory Standards. 1993. Standard methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically. Approved standard M7-A3. National Committee for Clinical Laboratory Standards, Villanova, Pa.
22. National Committee for Clinical Laboratory Standards. 1994. Perforance standards for antimicrobial susceptibility testing. Fifth informational supplement M100-S5. National Committee for Clinical Laboratory Standards, Villanova, Pa.
23. Neu, H. C., and N. Chin. 1989. In vitro activity of 5-ofloxacin. Antimicrob. Agents. Chemother. 33:1105-1107.
24. Pfaller, M. A., A. L. Barry, and P. C. Fuchs. 1993. Levofloxacin disk potency and tentative interpretive criteria for susceptibility tests. J. Clin. Microbiol. 31:1924-1926.
25. Shalit, I., S. A. Berger, A. Gorea, and H. Frimerman. 1989. Widespread quinolone resistance among methicillin-resistant Staphylococcus aureus isolates in a general hospital. Antimicrob. Agents Chemother. 33:593-594.
26. Sutton, L. D., and R. N. Jones. 1995. Suggested modifications for disk diffusion susceptibility testing criteria for levofloxacin and sparfloxacin following tests with a predictor panel of ciprofloxacin-resistant clinical isolates. J. Clin. Microbiol. 33:146-148.
27. Une, T., T. Fujimoto, K. Sato, and Y. Osada. 1988. In vitro activity of DR-3355, an optically active ofloxacin. Antimicrob. Agents Chemother. 32: 1336-1340.
28. Venezio, F. R., W. Tatarowicz, C. A. DiVincenzo, and J. P. O'Keefe. 1986. Activity of ciprofloxacin against multiply resistant strains of Pseudomonas aeruginosa, Staphylococcus epidermidis, and group JK corynebacteria. Antimicrob. Agents Chemother. 30:940-941.
29. Yamane, N., R. N. Jones, R. Frei, D. J. Hoban, A. C. Pignatari, and F. Marco. 1994. Levofloxacin in vitro activity: results from an international comparative study with ofloxacin and ciprofloxacin. J. Chemother. 6:83-91.